Treatment of short children born small for gestational age: US perspective, 2005.
Growth hormone (GH) administration to ameliorate growth deficiency of short children born small for gestational age (SGA) is currently approved in the US and the EU. Even though regulatory bodies from each examined similar datasets concerning GH treatment of short SGA children, the specifics of indications for treatment and recommended regimens differed with respect to GH dosage, age at which therapy might be initiated, and the degree of short stature required. US product labeling allows more flexibility but provides less guidance for the practitioner. The EU tends to be more proscriptive, limiting use to shorter children, restricting the dosage, and providing specific guidelines in terms of monitoring during treatment.
Chernausek
Steven D
SD
University of Cincinnati School of Medicine and Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA. steven.chernausek@cchmc.org
D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005317:Fetal Growth Retardation / Q000503:physiopathology; D013006:Growth Hormone / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D014481:United States
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone